Please assess the completion status of the following clinical trial:

Trial Title: Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 65 years;~* breast or lung cancer patients to receive docetaxel therapy as per protocol;~* corticosteroid administration, other than what is prescribed in this protocol, is not permitted during study participation, except topical administration and for adverse events;~* performance status ECOG 0-2;~* peripheral neuropathy ≤ 1;~* adequate kidney and liver functions~* signed study-specific informed consent~Exclusion Criteria:~* Patients who have received an investigational drug within 4 weeks of registration;~* Prior or concurrent malignancies (other than surgically treated carcinoma in situ;~* Serious medical or psychiatric illness which would prevent informed consent;~* Life expectancy \< 3 months;~* Active uncontrolled bacterial, viral, or fungal infection until these conditions are corrected or controlled.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).